Altamira Therapeutics Ltd.: xbrl:AccountingProfit
| Value | {"amount": -3969020, "currency": "USD"} |
|---|---|
| Period | 2023-01-01 – 2023-12-31 |
| Status | superseded |
| Entity | Altamira Therapeutics Ltd. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T16:24:25.793555+02:00
Raw response sha256:
Cite as: FACTANKER, https://factanker.com/fact/96169b25-4e93-4dbb-a65e-6f07d0f7ae36
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001213900-24-034940Retrieved: 2026-08-19T16:24:25.793555+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Cite as: FACTANKER, https://factanker.com/fact/96169b25-4e93-4dbb-a65e-6f07d0f7ae36
History
- no predecessors — first report